Clinical trial
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma: a Study Protocol of Prospective Single-center, Open Label and Exploratory Cohort Study (SNC-01)
NCT06388135 is registered in ClinicalTrials.gov with Yang Jianjun, PhD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma: a Study Protocol of Prospective Single-center, Open Label and Exploratory Cohort Study (SNC-01)
- Lead sponsor
- Yang Jianjun, PhD
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- May 1, 2024
- Completion date
- May 31, 2027
- Enrollment
- 80 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.